Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
Dhinesh Selvaraju, Clinical Pharmacist at Thanthai Periyar Government Headquarters Hospital, shared a post on LinkedIn:
“FDA Approval (2025): Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric Acquired TTP
Introduction
On December 23, 2025, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Cablivi (caplacizumab-yhdp), extending its use to pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP).
This marks the first FDA-approved treatment option specifically for pediatric patients with aTTP.
Indication
Caplacizumab is indicated for adults and pediatric patients aged 12 years and older with aTTP, in combination with therapeutic plasma exchange and immunosuppressive therapy.
Mechanism of Action
Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment. It binds to the A1 domain of vWF, preventing its interaction with platelet glycoprotein Ib.
This inhibits vWF-mediated platelet adhesion and microthrombus formation, a key process contributing to the pathophysiology of aTTP.
Clinical Evidence
The pediatric indication expansion was supported by a retrospective chart review involving 30 patients aged 2–18 years.
80% achieved clinical remission.
Clinical remission was defined by normalization of platelet count and LDH below 1.5 times the upper limit of normal, sustained for at least 30 days.
The evidence was observational rather than derived from a randomized pediatric controlled trial.
Safety and Monitoring
The principal safety concern is bleeding, which can be serious or fatal.
Important considerations include:
- Monitor for mucosal and other clinically significant bleeding.
- Exercise caution with concomitant anticoagulants and antiplatelet agents.
- Withhold treatment for 7 days before elective surgery or invasive procedures.
- Common adverse reactions include epistaxis and gingival bleeding.
Why this approval is important
This regulatory expansion extends access to a targeted anti-vWF therapy for adolescents with aTTP, a rare and potentially life-threatening thrombotic microangiopathy.
It also highlights the importance of integrating targeted inhibition of platelet adhesion with plasma exchange and immunosuppressive treatment in aTTP management.
References
- U.S. FDA. FDA Approves Therapy for Rare Blood Disorder in Pediatric Patients 12 Years and Older. January 5, 2026.
- U.S. FDA. CABLIVI Supplement Approval Letter, BLA 761112/S-018. December 23, 2025.
- HCPLive. FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP Therapy. January 2026.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series
-
Nov 20, 2026, 17:16Raising Awareness of Bleeding Disorders in Women Through the Red Flag Campaign – Perth Blood Institute
-
Nov 20, 2026, 15:11Muhammet Özbilen: Rivaroxaban vs Apixaban – The Menstrual Bleeding Difference
-
Nov 20, 2026, 14:54Fostamatinib in Immune Thrombocytopenia: Targeting Spleen Tyrosine Kinase to Reduce Platelet Destruction
-
Nov 20, 2026, 14:37Giuseppe Leone: The Evolving Treatment Landscape of Adult ITP
-
Nov 20, 2026, 14:25Sameer A.: When Heparin Triggers Thrombosis – A Case of HIT